A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

January 19, 2027

Study Completion Date

January 19, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986504

Specified dose on specified days

Trial Locations (12)

100142

Local Institution - 0001, Beijing

150081

Local Institution - 0006, Harbin

250117

Local Institution - 0007, Jinan

300060

Local Institution - 0012, Tianjin

350014

Local Institution - 0002, Fuzhou

453100

Local Institution - 0011, Xinxiang

510000

Local Institution - 0010, Guangzhou

518036

Local Institution - 0009, Shenzhen

241-8515

Local Institution - 0003, Yokohama-shi, Asahi-ku

135-8550

Local Institution - 0004, Koto-ku

104-0045

Local Institution - 0005, Chūōku

411-8777

Local Institution - 0008, Sunto-gun

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT07077434 - A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter